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Abstract
Purpose: Pancreatic cancer is one of the most lethal of solid tumors and is associated with aggressive cancer
biology. The purpose is to review the role of trypsin and effect on molecular and cellular processes potentially
explaining the aggressive biology in pancreatic cancer.
Methods: A narrative literature review of studies investigating trypsin and its effect on protease systems in can-
cer, with special reference to pancreatic cancer biology.
Results: Proteases, such as trypsin, provides a significant advantage to developing tumors through the ability to
remodel the extracellular matrix, promote cell invasion and migration, and facilitate angiogenesis. Trypsin is a
digestive enzyme produced by the exocrine pancreas that is also related to mechanisms of proliferation, invasion
and metastasis. Several of these mechanisms may be co-regulated or influenced by activation of proteinase-
activated receptor 2 (PAR-2). The current role in pancreatic cancer is not clear but emerging data suggest several
potential mechanisms. Trypsin may act as a Trojan horse in the pancreatic gland, facilitating several molecular
pathways from the onset, which leads to rapid progression of the disease. Pancreatic cancer cell lines containing
PAR-2 proliferate upon exposure to trypsin, whereas cancer cell lines not containing PAR-2 fail to proliferate upon
trypsin expression. Several mechanisms of action include a proinflammatory environment, signals inducing pro-
liferation and migration, and direct and indirect evidence for mechanisms promoting invasion and metastasis.
Novel techniques (such as organoid models) and increased understanding of mechanisms (such as the micro-
biome) may yield improved understanding into the role of trypsin in pancreatic carcinogenesis.
Conclusion: Trypsin is naturally present in the pancreatic gland and may experience pathological activation in-
tracellularly and in the neoplastic environment, which speeds up molecular mechanisms of proliferation, invasion,
and metastasis. Further investigation of these processes will provide important insights into how pancreatic can-
cer evolves, and suggest new ways for treatment.
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Introduction
Pancreatic cancer is one of the most lethal solid organ
tumors and is estimated to become one of the top two
leading causes to cancer deaths within the next decade.1
Patients with pancreatic cancer experience a very poor
survival with <5% to 6% being alive >5 years after diag-
nosis. The lack of real progress in pancreatic cancer
over the past decades is of concern, although progress
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in the characterization at a genomic level has brought
the understanding of disease characteristics and hetero-
geneity forward.2 However, pancreatic cancer demon-
strates features of aggressive biology; early invasiveness
even in smaller tumors with frequent perineural infiltra-
tion and a strong desmoplastic stromal response, render-
ing tumors resistant to most forms of therapy.3,4 In a
large population-based study of patients with pancreatic
cancer, investigators identified a subgroup of patients
with small cancers (<0.5 cm) at diagnosis, of which al-
most one third (31%) already had metastasis at the
time of diagnosis.5 The propensity to metastasize into
the liver is believed to start early and likely involve the
tumor stroma, with exosomes or vesicles secreted into
the circulation, creating docks for circulating tumor
cells to settle into so-called premetastatic niches in the
liver.6 However, many of these aggressive features are
not unique to pancreatic cancer and may only partly ex-
plain the uniquely aggressive biology seen in pancreatic
ductal adenocarcinoma (PDAC) compared to other
solid organ cancers.7 Thus, understanding the peritu-
moral stroma and its interaction with tumor cells and
stromal cells is increasingly perceived as an essential
clue to defeat this deadly disease.
Trypsin, a digestive enzyme secreted by the pancreas,
has been proposed to have a role in cancer growth.8 In
pancreatic cancer, trypsin may act as a culprit in the de-
velopment and progression through yet not fully eluci-
dated mechanisms, hypothesized to be an endogenous
signal within the pancreatic environment that fosters
invasiveness and metastatic potential. Potential mecha-
nisms are discussed, including findings from extrap-
ancreatic cancers and in pancreatic precursor lesions,
with the potential for improved understanding of pan-
creatic cancer.
An Enemy Within: A Trojan Horse
to Cancer Invasiveness?
In Greek mythology, the story of the ‘‘Trojan horse’’ tells
how the Greeks entered Troy and won the war after
many years of futile siege. The Greeks did this by build-
ing a large wooden horse—containing a force of Greek
warriors inside—that was left as a gift to the Trojans,
while pretending to leave the city. When taken inside
the city, the warriors embarked from the horse and let
the rest of the Greek army inside the city walls (Fig. 1).
Metaphorically speaking, a ‘‘Trojan Horse’’ has come
to mean any trick or stratagem that causes a target to
invite a foe into a securely protected bastion or place,
or; refers to subversion introduced from the outside;
or, more recently, applied to deceptively benign com-
puter codes that seem like legitimate applications but
are written to damage or disrupt a computer program.
Trypsin, it seems, may have the above capabilities to
circumvent a siege to a full-blown attack in pancreatic
cancer. Intrinsically, trypsin is located within the pan-
creatic gland by production in the pancreatic acini. Its
legitimate location within the cell is under normal cir-
cumstances held in a ‘‘checks-and-balances’’ state to
avoid premature activation or, activation in the wrong
location. However, during neoplastic development, cel-
lular stress and inflammation may lead to release of
trypsin into compartments otherwise protected from
this enzyme. The premature activation or, even intracel-
lular activation, of other types of proteases has been
demonstrated to be important mechanism to disease
states through mechanisms hitherto poorly understood
or scarcely investigated.9 Premature release and activa-
tion in the cell or leaks of trypsin into the stroma may
facilitate activation of enzyme cascades, leading to cellu-
lar proliferation, migration, invasion, angiogenesis, and
metastasis (Fig. 1). Such mechanisms have been demon-
strated in pancreatitis.10–13 Indeed, investigators have
identified the activation of trypsinogen within endocytic
vacuoles, cellular organelles that appear in pancreatic
acinar cells and treated with the inducers of acute pan-
creatitis.14 Endocytic vacuoles are formed as a result of
aberrant compound exocytosis and subsequent inter-
nalization of postexocytic structures. Notably, endocytic
vacuoles can undergo intracellular rupture and fusion
with the plasma membrane, providing trypsin with
access to cytoplasmic and extracellular targets.14 Thus,
trypsin may help explain why pancreas cancer is among
the most lethal, aggressive form of human cancers, usually
presents at a locally advanced stage at time of diagnosis,
with an invasive and metastatic nature unfamiliar to
most other solid organ cancers.15
Trypsin Is a Trojan Horse in Pancreas
Cancer Invasion
Trypsin (or, its proenzyme/zymogen trypsinogen) is a
serine protease and pancreatic digestive enzyme se-
creted and activated in the duodenum, and commonly
known to facilitate digestion by cleaving peptide that
make up proteins. Also, trypsin has been known for
years to be expressed in several isoforms—at least
six16 of which three are found in humans.17 All are
found in the pancreas, but some are also found extrap-
ancreatic such as mesotrypsin, which is also expressed
in neurological tissues.18 Furthermore, trypsin is expressed
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in cancerous tissues of several organs and has been
demonstrated to facilitate proliferation, invasion, and
metastasis.8,19–23 Notably, trypsin expression in non-
pancreas solid organ tumors is related to advanced dis-
ease stages and poor prognosis.8,19,21,24
One particular characteristic feature of PDAC is the
desmoplastic growth pattern and abundant stroma (usu-
ally about 70% of the tumor mass) that in part explains
the therapeutic resistance and low access to most che-
motherapy regimens.3 This desmoplastic stroma and
hypovascular environment are also increasingly viewed
as both a cause to cancer progression and a potential
therapeutical target.25 Also, the infiltrative nature
means that the tumor can include normal pancreas
containing exocrine epithelium that secretes digestive
enzymes, such as trypsin. Furthermore, studies show
that trypsin-sensitive cancer-cell subpopulation express
higher levels of slug, snail, vimentin, and N-cadherin
while they show a lack of expression of E-cadherin and
claudin, being profile characteristic of the epithelial-to-
mesenchymal transition.26 Epithelial-to-mesenchymal
transition confers metastatic properties to cancer cells
by enhancing mobility, invasion, and resistance to apo-
ptotic signals.27 In cellular culture (breast and colorectal
FIG. 1. An analogy of trypsin as a Trojan horse in pancreatic cancer. Depicted is to the left (1) the normal
checks-and-balances between intraluminal release of trypsinogen only activated into trypsin by EP in the
duodenum. This is the analogy to the ‘‘siege’’ or, ‘‘closed doors’’ were indolent/inactive warriors are barred from
action due to the active barriers and regulators. With neoplastic transformation (2), trypsin may be prematurely
activated either within the cell (which activate cascades), at the luminal side of epithelial cells, or in the stroma
due to leaks as integrity of cellular structures weakens (e.g., due to inflammation) or active transport by
endovesical transport mechanisms. Trypsin may (3) act as a catalyst to several downstream effects, likely with
PAR-2 as an important activator both at the luminal side and in the stroma, through which (4) proliferation,
invasion, and metastasis is then facilitated through several molecular mechanisms. The analogy serves to
illustrate for educational purposes the likelihood of an activator (enemy) within the cell (city walls) that break
down the natural barriers. See main body of text for further details. EP, enteropeptidase; PAR-2, proteinase-
activated receptor 2.
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cancer cells), experiments have shown that trypsin-
sensitive (easily detached cells based on short wash-out
with low concentration trypsin) show cancer stem cell-
like features, increased proliferation, and higher self-
renewal ability.26 Thus, the role of trypsin in pancreatic
cancer proliferation, invasion, and metastasis is of clini-
cal relevance. Indeed, it may be that the activation of
trypsin in and around stroma and neoplastic cells fosters
a more rapid and aggressive biological behavior that is
unparalleled to most other solid cancers. The presence
of trypsin in this environment may facilitate activation
of cell signaling mechanisms that speed the progression
and aggressiveness of the tumor.
Trypsin May Be Involved in the Early Siege
and (Pre)neoplasia Development
Trypsin acts through a controlled ‘‘checks-and-balances’’
system,28 for which the proenzyme trypsinogen is usually
first activated by an enteropeptidase to trypsin (Fig. 1)
when entering the duodenum (indeed, a far distance
away from the pancreatic acini and endothelial cells),
thus preventing premature activation and autodigestion
within the pancreatic duct (which may lead to acute pan-
creatitis). Notably, trypsin is highly elevated in serum of
patients with acute pancreatitis,29 suggesting leak into or
uptake into the blood stream, likely via the capillary sys-
tem within the gland. Trypsin inhibitors are in place to
avoid premature activation in the wrong location. One
such inhibitor is pancreatic secretory trypsin inhibitor
(PSTI), also called tumor-associated trypsin inhibitor
or SPINK1 when investigated outside the pancreas.30
Studies have shown somatic mutations of the cationic
trypsinogen gene (PRSS1) in patients with (hereditary)
chronic pancreatitis and pancreatic cancer.31 Although
the risk for pancreatic cancer may be lower than previ-
ously thought,31 it may serve as a model for the role of
pathological intracellular activation of trypsin that also
play a role in pancreatic cancerogenesis.32–34 However,
direct mutation in the gene is unlikely to be the expla-
nation in the vast majority of patients with PDAC, al-
though being a likely key component in the risk of
families with hereditary pancreatitis.31,35
Trypsin in pancreatic precursor and other
neoplastic lesions of the pancreas
Trypsin has proliferative capacity, as demonstrated in
several studies.8,20,21,23 Thus, trypsin may be involved
in early neoplasia development. This is indicated by
findings in preneoplastic lesions of the pancreas (intra-
ductal papillary mucinous neoplasia [IPMNs]), where
expression of several proteins in pancreatic juice from
patients with IPMNs was significantly higher com-
pared with that in other pancreatic diseases. Notably,
the most significant protein was PSTI.36 Although
this study found the increased pancreatic juice expres-
sion to be related to IPMNs only (and not pancreatic
ductal carcinoma) and the expression of trypsin per
se was not investigated, it would suggest that the inhib-
itor is increased in either a response to increased tryp-
sin activity or acts as an upregulated protein by itself
and, thus, acts as a pro-neoplastic factor. The fact that
upregulation of PSTI may be an effect of increased tryp-
sin expression and/or activation is indirectly confirmed
in another study, which found moderate to strong ex-
pression of trypsin in preneoplastic lesion of the pan-
creas, including mucinous cysts and IPMNs.37 In a
further matched case–control study of over 33,000 in-
habitants among which 84 developed pancreatic cancer,
there appeared to be a relation between lower levels of
PSTI in relation to trypsin for those who developed can-
cer, suggesting that a loss of inhibitor-function may pose
a risk for subsequent pancreatic cancer development.38
A further indirect evidence that trypsin may have a
role in preneoplasia development and aggressive pheno-
type comes from studies of a rare type of tumor called
intraductal tubulopapillary neoplasm of the pancreas
(ITNP). This rare tumor has an overall very good prog-
nosis (unlike PDAC) with most patients being cured
by resection, or showing very good long-term outcome,
even in presence of invasive components. Notably, this
type of tumor in the pancreas stains all negative for tryp-
sin on immunohistochemistry,39,40 indicating that the
lack of trypsin activation or tissue leak confers a good bi-
ology in this instance. Hence, there appears to be a pat-
tern of trypsin expression related to biology of PDAC,
related to precursors as in IPMN, but absent in ‘‘good’’
biology tumors such as the ITNPs.
Among the several molecular classes that are sug-
gested in pancreatic cancer41 is a squamous group, fre-
quently found in body and tail cancers with poor
prognosis.42 Currently it is not known whether the
squamous phenotype is a distinct group of tumors or
represent a continuum in development (e.g., morpho-
logical transformation along a continuum). Notably,
trypsin has been reported to have a particular role in
squamous cancers, where trypsin-2 activated matrix
metalloproteinases (MMPs) such as MMP-9 facilitate
invasion and metastasis.43 While the trypsin-activation
of MMPs remains to be specifically investigated in pan-
creatic cancer, the principle is demonstrated for
Søreide, et al.; Journal of Pancreatic Cancer 2020, 6.1
http://online.liebertpub.com/doi/10.1089/pancan.2019.0014
15
squamous oral cancer.44 However, a recent study found
matric metalloproteinases (MMPs 9 and 1) to be
among 10 essential so-called hub genes in predicting
prognosis in pancreatic cancer.45 Also, expression of
several MMPs (MMP-1, -2, -7, and -9) were investi-
gated in a set of IPMNs (known precursors to PDAC)
and the MMP expression correlated with the histologi-
cal grade, type, and invasion of these IPMNs, with
higher expression score of MMPs conferring a poorer
prognosis.46
Proteinase-Activated Receptor 2
as an Important Co-Player
Proteases can also communicate directly to cells by acti-
vation of a unique group of transmembrane G-protein-
coupled receptors known as protease-activated receptors
(PAR). There are four mammalian PARs (PAR-1, -2, -3,
and -4), but most interesting in the current setting is
PAR-2. PAR-2 is overexpressed in several advanced
stage tumors and is activated by trypsin-like serine pro-
teases that are highly expressed or otherwise dysregulated
in several types of cancers.47 The several mechanisms of
action that are found in PAR-2 related cancerogenesis
and for several tumors are reviewed in detail elsewhere.47
Previous studies have established a link between tryp-
sin expression and activated signaling systems—such as
PAR-2—with effect on cancer growth of pancreatic can-
cers.47–51 Very high expression of PAR-2 has been found
in certain tumor cell lines derived from the lung, colon,
and pancreas.52 Pancreatic cancer cell lines containing
PAR-2 proliferate upon exposure to trypsin, whereas
the cancer cell line not containing PAR-2 failed to pro-
liferate upon trypsin exposure.23 This suggests that the
presence of PAR-2 is needed for trypsin to induce pro-
liferation in cancer cells. Another study found no prolif-
erative activity of PAR-2 on pancreatic cells, but a PAR-
2 dependent migration of pancreatic cells.53 The same
positive association with trypsin and PAR-2 expression
has been noted in cholangiocarcinoma cells,54 but not in
hepatocellular carcinoma, suggesting tumor tissue specific
ways of action and influence. The above findings may sug-
gest that PAR-2 may be a target for prevention of migra-
tion, invasion, and metastasis (Fig. 2) through pathways
activated and involved in pancreatic cancer progression.55
A further series of studies reported that PAR-2 may en-
hance tumorigenesis through crosstalk with transforming
growth factor-beta (TGF-beta) signaling to promote TGF-
beta1-induced cell migration/invasion and invasion-
associated gene expression in PDAC cells.55 Further ex-
perimental studies in cancer cell lines found that PAR-2
activation drives pancreatic cancer cell migration via
an EGF-Src-Rac-p38/mitogen-activated protein ki-
nase kinase/EGF1/2 signaling pathway, which is facil-
itated by extracellular ATP levels.53 Also, PAR-2 is
shown to introduce inflammatory signaling56 by cyto-
kine release and cyclooxygenase expression,57 which
may enhance the inflammatory milieu. Hence, several
modes of action appear possible by PAR-2 activation
with downstream effect on cancer biology (Fig. 2). Of
note, one study found that trypsin-PAR-2 signaling
contributes to pancreatic cancer pain in vivo,48 a finding
that may be clinically relevant as pain is a common clin-
ical feature for patients with pancreatic cancer.
Why Has Trypsin Yet to Be Investigated
as a Major Player Before in Pancreatic Cancer?
Several methodological issues may explain why trypsin is
poorly investigated in pancreatic cancer. First, trypsin is
present in abundance in pancreatic tissue due to the
physiological exocrine function of the gland, thus the
typical dichotomization done in research (high vs. low)
may not apply, as it is already present in high amounts
even in normal tissue. Second, evaluation of trypsin
with immunohistochemistry is difficult as it is not a
clear-cut stain by use of most antigens, but often patchy
and diffuse with hard to quantify cutoffs and no robust
scores for quantification.
Further, gene expression may not reveal significant
differences between normal and neoplastic tissue as
trypsinogen is omnipresent in pancreatic tissue and
ductal epithelial cells due to the physiological function
of the exocrine role of the pancreas. In 1 study of 65 pa-
tients with pancreatic cancer, 8 (12.3%) patients had
mutation in the serine protease 1 gene (PRSS1) coding
for the cationic trypsinogen (trypsin 1),33 with corre-
sponding higher serum levels of trypsin compared to
nonmutated cancers and controls. In another series
of patients, mutation of PRSS1 did not seem to play a
role in terms of pancreatic cancer development.34 It
may thus be that mutations in the gene is not the essen-
tial change affecting pancreatic cancers, but rather the
already present and physiological production of trypsin
may be what drives cancer progression. Indeed, at a ge-
netic level it is demonstrated that there is little hetero-
geneity in driver genes in metastatic disease,58 thus
other alterations may be essential in contributing to in-
vasion and metastasis after cancer has first developed.
For studies involving RNA investigation, the intro-
duction of trypsinization as part of the experimental
process results in a complete degradation of RNA
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regardless of cell line type, differentiation stage, or pas-
sage number.59 Thus, findings from RNA studies may
not rely on high/low dichotomization but rather on
trypsin as present, and therefore acting as a modifier
or catalyst of other processes that drive further prolif-
eration and invasive process in pancreatic cancer.
Further, the fact that trypsin is a standard reagent in
proteomics experiments but is usually not considered
in database searches may lead to a number of false-
positive findings. As both lysine and arginine residues
are cleavage sites of trypsin, the nearly exclusive use of
trypsin as the protein digestion enzyme in shotgun pro-
teomic analyses hinders the detection of transcriptomic
alterations, such as seen in junction-spanning peptides.60
In proteomic sciences, when cellular protein fractions
corresponding to cytosol, membrane, nucleus, and cyto-
skeleton are further prepared for mass-spectrometry,
trypsinization of peptides is a standard step in the pro-
cess.61 Thus, for protein expression, trypsin may not be
recognized as an entity of its own in the results, due to
the laboratory introduced step of trypsinization that is
done to digest proteins before proteomic (or, peptide)
investigation. Also, trypsinization may lead to over-
abundance of peptides that otherwise would be quanti-
tatively different between groups with high or low levels
of trypsin, for example, in pancreatic cancers. This
may, despite its purpose, lead to multiple false-positive
findings from the experiments itself, as recently dem-
onstrated.62 One may thus ask whether trypsinization
in such experiments potentially mask the findings of
peptides or activated constituents that stem from the
native or cancer-driven trypsin-related activity.
FIG. 2. Trypsin activation of PAR-2 with downstream effects. The insert shows how PAR-2 may play a role
through early stages of neoplasia progression (PanIN sequences), whereas the upstream and downstream
mechanisms are shown in relation to a tentative endothelial cell. Upstream effects may be solicited through
pathological stimulus (external or intrinsic to the cell) that further lead to inflammation, trypsin activation, and
secretion. PAR-2 may become activated on the luminal side, with ensuing downstream effects on calcium-
metabolism, inflammation, nuclear signaling, and resultant protumorigenic effects. Stromal components are
involved, including proteinases of the extracellular microenvironment and cancer-associated fibroblasts.
Simplistic overview for the purpose of clarity.
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The same problem holds for tissue cultures, which are
often trypsinized to detach cells and allow for isolation of
cells in suspensions. Only more recently has such lab ar-
tifacts been recognized to cause differences in results,
particularly when investigating metabolites.63
Further, novel techniques are in their infancy but
may yield new ways to investigate and explore cell be-
havior. Organoids or 3D cell cultures may be one such
opportunity.64 Cancer cells have historically been ex-
amined using 2D culture methods. However, the mor-
phology, cell-to-cell and cell-to-matrix adhesions, and
cellular differentiation of cells grown in 2D culture sys-
tems might differ from those growing in vivo. Recently,
a study using a 3D culture showed that cytokeratin 7,
trypsin, CA19-9, and E-cadherin were highly expressed
in PK-1 cells but not in PANC-1 cells.65 Such differ-
ences may have gone undetected in the past and may
only now be understood through further research by
appreciating variance in cell cultures, cell lines, and
in specimens from different patients.
Finally, the more recent revolution related to the asso-
ciation of the microbiome66 and fungal67 involvement in
pancreatic precursors68 and carcinogenesis66,68,69 may
open avenues for new understanding of mechanisms
hitherto not explored. It is assumed that the microbiome
is present long before a cancer is clinically detected in the
pancreas. Currently, no direct evidence exists between
any bacteria or fungi related to trypsin activation in
early carcinogenesis. However, a clinical study in patients
who underwent resection and developed postoperative
pancreatic fistulae (POPF) found that Pseudomonas
aeruginosa and Enterobacter cloacae isolated from
drainage fluid in patients with clinically relevant
(grade B/C) POPF could cause trypsinogen activa-
tion.70 The investigators further found that trypsino-
gen activation by P. aeruginosa and E. cloacae were
preventable by the use of a serine protease inhibitor
in vitro and that a protease in the supernatant from
P. aeruginosa-positive cultures acted as the trypsino-
gen activator.70 Again, this is extrapolation from
data from a different setting, but serves to show that
certain bacteria have the ability to activate trypsino-
gen into trypsin and thereby eliciting effects that
may have clinical relevance (Figs. 1 and 2).
Conclusion
Trypsin may act as a Trojan horse in PDAC biology.
While some may find this to be a forced analogy, we
do not intend it to be taken literally. The analogy, al-
though imperfect, serves to illustrate that factors leading
to an accelerated breakdown within cells and in stroma
may hold key information to the poorly understood and
exceedingly bad biology of pancreatic cancer (Table 1).
Clearly, there must be factors in PDAC that render this
form of cancer so exceptionally aggressive and new av-
enues of research and biological understanding must be
sought to improve clinical care. We agree that the anal-
ogy may be stretched at this time (due to the actual lack
of data to support it beyond the indirect evidence and
extrapolation from other tumors). However, as argued
in this article, the trypsin effect in cancer may be a con-
sequence of ‘‘Trojan horse’’ transport or dislocation
(which may be due to endovesical transport or other
pathological dislocation) into compartments where
trypsin should not be, including premature intraluminal
activation or transport and activation into stromal com-
partments. Currently, data are incomplete and patchy,
we have tried to draw up the lines between existing
data and the lack of direct evidence. Connection of
the dots and the missing links is still needed in this field.
Trypsin is present in the pancreatic gland and may
experience pathological activation in the (pre-)neoplastic
environment, which may speed up molecular mechanisms
Table 1. Current Understanding and Hypotheses
to the Role of Trypsin in Pancreatic Cancer
Trypsin is native to the pancreatic gland and hence pathological
exposure may occur early in carcinogenesis
Mechanisms of intracellular activation and extracellular vesicle transport
of trypsinogen has been demonstrated in pancreatitis and
experimental research. The same mechanisms may be available in
neoplasia
Mutation in trypsinogen-gen PRSS1 confers risk for pancreatitis and
pancreatic cancer
Trypsin leakage causes cellular proliferation in pancreatitis
Trypsin expression is found to be increased in pancreatic precursors,
such as IPMNs
Indolent tumors of the pancreas, such as ITNPs, does not stain for trypsin
Several factors that may be activated by trypsin, including PAR-2 and
MMPs, are strongly associated with cell proliferation, invasion, and
metastatic potential
PAR-2 is a ligand for trypsin, facilitating cellular growth or migration
in vitro if both are present
PAR-2-signaling is proinflammatory, which may cause trypsin leakage in
to the peritumoral stroma
G-protein-coupled receptors, of which trypsin is a ligand, are related to
carcinogenesis
Extrapancreatic data
Increased trypsin expression has been found in aggressive tumors of
the digestive tract, prostate, lung, oral cavity, and other tumors.
Expression of trypsin has been related to activation of MMPs and
mechanisms in the tumor microenvironment conferring aggressive
biology and poor outcome
Nonpancreatic cancer cell lines treated with trypsin gain features seen
in cancer stem cells
IPMNs, intraductal papillary mucinous neoplasia; ITNPs, intraductal
tubulopapillary neoplasm of the pancreas; MMPs, matrix metalloprotei-
nases; PAR-2, proteinase-activated receptor 2.
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of proliferation, invasion, and metastasis. PAR-2 may be
an essential co-lead for several of these processes. Novel
and emerging techniques, including the use of organoid
cultures and investigation of the microbiome may give
further insight into how trypsin may be activated and
play a role in pancreatic carcinogenesis, potentially even
from an early onset. Further investigation of these pro-
cesses will provide important insights into how pancreatic
cancer evolves, and suggest new ways for detection, pre-
vention, and treatment.
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